Loading...
XNAS
COLL
Market cap1.51bUSD
Dec 05, Last price  
47.91USD
1D
1.01%
1Q
25.03%
Jan 2017
207.71%
IPO
269.96%
Name

Collegium Pharmaceutical Inc

Chart & Performance

D1W1MN
XNAS:COLL chart
P/E
21.89
P/S
2.40
EPS
2.19
Div Yield, %
Shrs. gr., 5y
3.86%
Rev. gr., 5y
16.31%
Revenues
631m
+11.41%
0001,711,00028,476,000280,413,000296,701,000310,016,000276,868,000463,933,000566,767,000631,449,000
Net income
69m
+43.68%
-16,197,000-17,917,000-27,255,000-94,176,000-74,865,000-39,128,000-8,148,00026,752,00071,517,000-25,002,00048,155,00069,190,000
CFO
205m
-25.39%
-16,530,000-17,947,000-21,567,000-75,053,000-67,018,000169,390,00027,783,00093,942,000103,557,000124,230,000274,749,000204,980,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
IPO date
May 07, 2015
Employees
207
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT